Skip to main content

Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN


Purpose of Review

To provide a general overview of the organizations dedicated to advance clinical and translational research in the field of psoriatic disease and to describe the current and future opportunities for team science approaches to overcome unmet needs in the field. Descriptions of initiatives from the NPF, PPACMAN, and GRAPPA are summarized.

Recent Findings

Program projects have recently identified areas of knowledge gaps in diagnosis, treatment, and prevention of psoriasis and psoriatic arthritis (PsA). NPF’s Psoriasis Prevention Initiative aims to identify interventions that can prevent the onset and relapse of psoriatic disease or related comorbidities. The Psorcast Study is a joint venture between PPACMAN and Sage Bionetworks based on patient-generated smartphone measurements of psoriatic disease. Similarly, GRAPPA is involved in a number of projects related to axial PsA, enthesitis prevalence, and biomarker discoveries.


As important initiatives bring new targets for diagnosis and therapeutics in psoriatic disease, supra-endeavors such as the NIH-Accelerating Medicines Partnership (AMP) and the European Innovative Medicines Initiative (IMI) are promising public-private partnerships that can significantly catapult the field forward.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ritchlin C, Scher JU. Strategies to improve outcomes in psoriatic arthritis. Curr Rheumatol Rep. 2019;21:72.

    Article  PubMed  Google Scholar 

  2. •• Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15:153–66. study provides a comprehensive description of risk factors for transition from psoriasis to psoriatic arthritis and discusses clinical, demograophic, and molecukar features that can predict this progression.

    Article  PubMed  Google Scholar 

  3. NIAMS. Roundtable on Gaps and Emerging Opportunities in Psoriatic Arthritis. (2017).

  4. Waxman R, et al. Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting. J Rheumatol Suppl. 2020;96:25–30.

    Article  PubMed  Google Scholar 

  5. Abstracts From. Cure symposium the future of psoriatic disease: prevention, precision medicine, and cure. Journal of Psoriasis and Psoriatic Arthritis. 2019;4(155–168):2019–168.

    Article  Google Scholar 

  6. Haberman R, Perez-Chada LM, Siegel E, Reginato AM, Webster D, Chandran V, et al. Psoriasis and psoriatic arthritis clinics multicenter advancement network consortium (PPACMAN) 2018 annual meeting summary. Journal of Psoriasis and Psoriatic Arthritis. 2020;5:68–72.

    Article  Google Scholar 

  7. National Psoriasis Foundation.

  8. Initiative, N. P. P. (2020).

  9. Okhovat JP, Ogdie A, Reddy SM, Rosen CF, Scher JU, Merola JF. Psoriasis and psoriatic arthritis clinics multicenter advancement network consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics. J Rheumatol. 2017;44:693–4.

    Article  PubMed  Google Scholar 

  10. Trister AD, Dorsey ER, Friend SH. Smartphones as new tools in the management and understanding of Parkinson’s disease. NPJ Parkinsons Dis. 2016;2:16006.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bot BM, Suver C, Neto EC, Kellen M, Klein A, Bare C, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Sci Data. 2016;3:160011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Omberg L, Chaibub Neto E, Mangravite LM. Data science approaches for effective use of mobile device-based collection of real-world data. Clin Pharmacol Ther. 2020;107:719–21.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Doerr M, Maguire Truong A, Bot BM, Wilbanks J, Suver C, Mangravite LM. Formative evaluation of participant experience with mobile eConsent in the app-mediated Parkinson mPower study: a mixed methods study. JMIR Mhealth Uhealth. 2017;5:e14.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Webster DE, Suver C, Doerr M, Mounts E, Domenico L, Petrie T, et al. The Mole Mapper study, mobile phone skin imaging and melanoma risk data collected using ResearchKit. Sci Data. 2017;4:170005.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–71.

    Article  PubMed  Google Scholar 

  16. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

    Article  PubMed  Google Scholar 

  17. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986–91.

    Article  PubMed  Google Scholar 

  18. Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, et al. GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. Ann Rheum Dis. 2018;77:e23-e23.

    Article  Google Scholar 

  19. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Goldman M. The innovative medicines initiative: a European response to the innovation challenge. Clin Pharmacol Ther. 2012;91:418–25.

    Article  CAS  PubMed  Google Scholar 

  21. • Dolgin E. Massive NIH-industry project opens portals to target validation. Nat Rev Drug Discov. 2019. study provides a description of how public-private partnerships through NIH-led initiatives can accelerate the discovery of novel targes in inflammatory conditions.

  22. Zhang F, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019;20:928–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mizoguchi F, Slowikowski K, Wei K, Marshall JL, Rao DA, Chang SK, et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun. 2018;9:789.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Der E, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019;20:915–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Afifi L, Shankle L, Armstrong AW, Boas M, Bridges A, Chiguil V, et al. National Psoriasis Foundation priorities for patient-centered research: proceedings from the 2016 conference. J Psoriasis Psoriatic Arthritis. 2017;2:73–80.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


NIH/NIAMS R01AR074500-01A, National Psoriasis Foundation PsA Diagnostic Challenge and Psoriasis Prevention Initiative Grants, The Riley Family Foundation and The Snyder Family Foundation (Scher); NIH U01-AI119125, National Psoriasis Foundation Diagnostic Challenge Grant (Liao).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jose U. Scher.

Ethics declarations

Conflict of Interest

UCB, Janssen, Abbvie, Pfizer, Novartis, Sanofi, BMS (Scher); AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Corrona (Ogdie); AbbVie, Lilly, Janssen, Novartis, BMS, Pfizer, Amgen, UCB (FitzGerald); Abbvie, Amgen, Janssen, Novartis, Pfizer, Regeneron, and TRex Bio (Liao)BMS, Abbvie, Dermavant, Lilly, Novartis, Janssen, UCB, Sun Pharma, Pfizer, EMD Sorono (Merola). Novartis, Janssen, Pfizer, Otsuka (Webster).

Human and Animal Rights and Informed Consent

As this is a review article, this article does not contain any studies with human or animal subjects.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Psoriatic Arthritis

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bell, S., Merola, J.F., Webster, D.E. et al. Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Curr Rheumatol Rep 22, 78 (2020).

Download citation

  • Published:

  • DOI: